v3.26.1
Group Information (Tables)
12 Months Ended
Dec. 31, 2025
Interests In Other Entities [Abstract]  
Summary of Information about Subsidiaries The consolidated financial statements include the following subsidiaries:
% equity interest
Name
Country of
incorporation
Registered office
December 31,
2025
December 31,
2024
BioNTech BioNTainer Holding GmbH
Germany
Mainz
100%
100%
BioNTech Cell & Gene Therapies GmbH
Germany
Mainz
100%
100%
BioNTech Collaborations GmbH
Germany
Mainz
100%
100%
BioNTech Delivery Technologies GmbH
Germany
Halle
100%
100%
BioNTech Diagnostics GmbH
Germany
Mainz
100%
100%
BioNTech Discovery GmbH
Germany
Mainz
100%
n / a(1)
BioNTech Europe GmbH
Germany
Mainz
100%
100%
BioNTech Idar-Oberstein Services GmbH
Germany
Idar-Oberstein
100%
100%
BioNTech Innovation and Services Marburg GmbH
Germany
Marburg
100%
100%
BioNTech Innovation GmbH
Germany
Mainz
100%
100%
BioNTech Innovative Manufacturing Services GmbH
Germany
Idar-Oberstein
100%
100%
BioNTech Manufacturing GmbH
Germany
Mainz
100%
100%
BioNTech Manufacturing Marburg GmbH
Germany
Marburg
100%
100%
BioNTech Real Estate Holding GmbH
Germany
Holzkirchen
100%
100%
CureVac Corporate Services GmbH
Germany
Tübingen
86.75%(2)
n / a(1)
CureVac Manufacturing GmbH
Germany
Tübingen
86.75%(2)
n / a(1)
CureVac SE
Germany
Tübingen
86.75%(2)
n / a(1)
InstaDeep DE GmbH
Germany
Berlin
100%
100%
Continued on next page
% equity interest
Name
Country of
incorporation
Registered office
December 31,
2025
December 31,
2024
JPT Peptide Technologies GmbH
Germany
Berlin
100%
100%
NT Security and Services GmbH
Germany
Mainz
100%
100%
reSano GmbH
Germany
Mainz
100%
100%
BioNTech Australia Pty Ltd.
Australia
Melbourne
100%
100%
BioNTech R&D (Austria) GmbH
Austria
Vienna
100%
100%
CureVac Belgium SA
Belgium
Ottignies-Louvain-
la-Neuve
86.75%(2)
n / a(1)
Biotheus (previously Simba Merger Sub)
Cayman Islands
George Town
100%
100%
BioNTech (Shanghai) Pharmaceuticals Co. Ltd.
China
Shanghai
100%
100%
Biotheus (Hengqin) Co. Ltd.
China
Zhuhai
100%
n / a(1)
Biotheus (Nantong) Co. Ltd.
China
Nantong
100%
n / a(1)
Biotheus (Suzhou) Co. Ltd.
China
Suzhou
100%
n / a(1)
Biotheus Inc.
China
Zhuhai
100%
n / a(1)
InstaDeep France SAS
France
Paris
100%
100%
Biotheus (Hong Kong) Ltd.
Hong Kong
Hong Kong
100%
n / a(1)
Cabt-Bio (Hong Kong) Ltd.
Hong Kong
Hong Kong
100%
n / a(1)
Biopharma BioNTech Israel Ltd.
Israel
Tel Aviv
100%
100%
New Technologies Re
Luxembourg
Luxembourg
100%
100%
CureVac Merger B.V.
Netherlands
Amsterdam
86.75%(2)
n / a(1)
CureVac N.V.
Netherlands
Amsterdam
86.75%(2)
n / a(1)
CureVac Netherlands B.V.
Netherlands
Amsterdam
86.75%(2)
n / a(1)
BioNTech Rwanda Ltd.
Rwanda
Kigali
100%
100%
BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.
Singapore
Singapore
100%
100%
BioNTech Pharmaceuticals Spain S.L
Spain
Barcelona
100%
100%
BioNTech Switzerland GmbH
Switzerland
Basel
100%
100%
CureVac Swiss AG
Switzerland
Basel
86.75%(2)
n / a(1)
InstaDeep Tunisia SARL
Tunisia
Tunis
100%
100%
BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret
Anonim Şirketi
Turkey
Istanbul
100%
100%
BioNTech UK Ltd.
United Kingdom
London
100%
100%
InstaDeep Ltd.
United Kingdom
London
100%
100%
BioNTech Delivery Technologies (US), LLC
United States
Cambridge
100%
100%
BioNTech Research and Development, Inc.
United States
Cambridge
100%
100%
BioNTech US Inc.
United States
Cambridge
100%
100%
BioNTech USA Holding, LLC
United States
Cambridge
100%
100%
CureVac Inc.
United States
Boston
86.75%(2)
n / a(1)
InstaDeep LLC
United States
Dover
100%
100%
JPT Peptide Technologies Inc.
United States
Cambridge
100%
100%
(1)Included during the year ended December 31, 2025.
(2)As of December 31, 2025, the subsidiary is fully consolidated in the consolidated financial statements as control was reached in December 2025,
and no non-controlling interests existed as of December 31, 2025. As of the acquisition date all closing conditions related to the completion of the
post-offer reorganization have been satisfied, even though the tendered shares amount to 86.75% as of December 31, 2025, and reached 100%
with the back-end measures as of January 6, 2026 (for details see Note 5).
Summary of Information about Parent Company ATHOS KG, Holzkirchen, Germany, is the sole shareholder of AT Impf GmbH, Munich, Germany, and beneficial
owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT
Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables
it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM.
Ownership of ordinary shares in
BioNTech (in %)
Name
Country of
incorporation
Registered office
December 31,
2025
December 31,
2024
AT Impf GmbH
Germany
Munich
40.30%
42.44%
Summary of Information about Entity with Significant Influence Over Group Medine GmbH, Mainz, Germany, owned the following percentage of ordinary shares in BioNTech at the following
dates as indicated:
Ownership of ordinary shares in
BioNTech (in %)
Name
Country of
incorporation
Registered office
December 31,
2025
December 31,
2024
Medine GmbH
Germany
Mainz
15.97%
16.85%